PT Phapros Tbk Launches Category 1 Daily Dose OAT Package to Support TB Treatment in Indonesia

JAKARTA, March 20, 2025 – PT Phapros Tbk, a national pharmaceutical company that has been established for more than six decades, remains committed to providing quality health products for the Indonesian people. PT Phapros Tbk, a subsidiary of the State-Owned Pharmaceutical Holding Company, officially launched the Category 1 Daily Dose OAT Package, an antituberculosis medication in the form of coated tablets. This launch is part of the company's efforts to support the government's program in controlling and treating tuberculosis (TB) in Indonesia.

Acting Director of PT Phapros Tbk, Ida Rahmi Kurniasih, stated that this innovation reflects the company's commitment to providing quality healthcare solutions for the community.

“As the country with the second-highest number of TB cases in the world after India, Indonesia requires effective and easily accessible solutions for patients. The Category 1 Daily Dose OAT Package is a generic version of the anti-tuberculosis medication designed in accordance with the recommendations of the World Health Organization (WHO),” she said.

The product is targeted to meet 38 percent of national demand by the end of 2025. Formulated in the form of coated tablets, the Category 1 Daily Dose OAT Package is designed to facilitate patient consumption and improve adherence to TB treatment.

“We hope this package can be part of the solution to reduce TB cases in Indonesia. We will continue to innovate to deliver pharmaceutical products that meet community needs and support national health programs,” added Ida Rahmi Kurniasih.

The launch of the Category 1 Daily Dose OAT Package further strengthens PT Phapros Tbk's portfolio in the antituberculosis drug category, in line with the company's mission to improve the quality of life through innovative and high-quality pharmaceutical products.

“We are optimistic that this sales target can be achieved through the various strategies we have implemented.”

The pharmaceutical sector remains attractive in 2025, including stocks of companies in the sector. Despite numerous challenges, the opportunities offered are also significant. The growing number of pharmaceutical companies in Indonesia, both in terms of drug production and medical devices as well as traditional herbal medicines, is a factor contributing to the bright outlook for the pharmaceutical market this year.